Results 161 to 170 of about 4,046,779 (307)

Stakeholders' Perceived Barriers and Successes of Quality Improvement Programs for Patients With Diabetes Comment on "Quality and Performance Measurement in Primary Diabetes Care: A Qualitative Study in Urban China". [PDF]

Int J Health Policy Manag, 2023
Neumann A.
europepmc   +1 more source

A tough nut to crack: performance measurement in specialist policing [PDF]

  As police forces worldwide increase the number of specialist units within their organisational structures, they require innovative performance measurement frameworks to properly evaluate the effectiveness of these units within the broader ...
Charl Crous, Zhivan Alach
core  

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Sustainable care quality improvement: a scoping literature review of performance measurement in lean healthcare implementations. [PDF]

BMC Health Serv Res
Pozzan C, Tiso A, Pamich C, Verbano C.
europepmc   +1 more source

Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention. [PDF]

Am J Psychiatry, 2023
Williams AR, Mauro CM, Feng T, Wilson A, Cruz A, Olfson M, Crystal S, Samples H, Chiodo L.   +8 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

The beast and the burden: will pruning performance measurement improve quality? [PDF]

BMJ Qual Saf
Schneider EC.
europepmc   +1 more source

Performance measurement and management in the British higher education sector. [PDF]

Qual Quant, 2022
Sheikh AZ, Chandler J, Hussain B, Timmons S.   +3 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Development of a Performance Measurement Framework for European Health Technology Assessment: Stakeholder-Centric Key Performance Indicators Identified in a Delphi Approach by the European Access Academy. [PDF]

J Mark Access Health Policy
Julian E, Xander NSH, Boumaki K, Garcia MJ, Jahimovica E, Mosset-Keane J, Otto MH, Pavlovic M, Scroccaro G, Strammiello V, Bernardini R, Capri S, Casado-Arroyo R, Desmet T, Van Dyck W, Fricke FU, Gianfrate F, Solà-Morales O, Wasem J, Wörmann BJ, Ruof J.   +20 more
europepmc   +1 more source